WELCOME TO THE XTRA PROGRAM
The XIAFLEX® Training Resources for Administration (XTRA) Program provides physicians and their offices access to all existing injector training, resources, and information about the managed distribution enrollment needed to get started with XIAFLEX®.
To determine the proper site for injection, locate the area where the contracting cord is maximally separated from the underlying flexor tendons, and where the skin is not intimately adhered to the cord.1
For complete details on the appropriate injection procedure for XIAFLEX®, visit the
Use of local anesthetic is not recommended prior to the injection procedure, as it may interfere with proper placement of the needle.1
However, local anesthetic may be used for the finger extension procedure to help with patient comfort.1
To learn more about the appropriate administration of XIAFLEX®, visit the
The finger extension procedure may be performed ~24 to 72 hours after the injection of XIAFLEX® if a contracture persists.1
Read more about performing the finger extension procedure on the
Yes. In fact, XIAFLEX® demonstrated efficacy in patients with PIP contractures up to 80 degrees.1
Learn more about how XIAFLEX® helped correct contractures and increased range of motion in PIP and MP joints on the
Only physicians who have completed the necessary training and enrollment can obtain and inject XIAFLEX®. Once a practice is enrolled in the managed distribution program, there are 2 ways to acquire XIAFLEX®—via a Specialty Distributor (Besse Medical) or a Specialty Pharmacy (US Bioservices).
For more information on the acquisition process, go to the Acquiring XIAFLEX® page.
Once you have completed the procedure training and enrolled in the XIAFLEX® managed distribution program, your practice is ready to schedule appropriate adult patients with Dupuytren’s contracture with a palpable cord to be treated with XIAFLEX®.
XIAFLEX® is indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord.
Schedule initial visit for the injection and follow-up visit for the finger extension procedure if the contracture persists
Important Safety Information for XIAFLEX®
XIAFLEX® is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord.
|1.||XIAFLEX® [package insert]. Malvern, PA: Endo Pharmaceuticals Inc.|
|2.|| Starkweather KD, Lattuga S, Hurst LC, et al. Collagenase in the treatment of Dupuytren’s disease: an in vitro study. J Hand Surg Am. |
|3.||Data on file. DOF-XDC-18. Endo Pharmaceuticals Inc; July 24, 2015.|
|4.||Desai SS, Hentz VR. The treatment of Dupuytren disease. J Hand Surg Am. 2011;36(5):936-942.|
|5.||Brandt KE. An evidence-based approach to Dupuytren’s contracture. Plast Reconstr Surg. 2010;126(6):2210-2215.|
|6.||Hay DC, Louie DL, Earp BE, Kaplan FT, Akelman E, Blazar PE. Surgical findings in the treatment of Dupuytren’s disease after initial treatment with clostridial collagenase (Xiaflex). J Hand Surg Eur Vol. 2014;39(5):463-465.|